Presicce Fabrizio, De Nunzio Cosimo, Tubaro Andrea
Department of Urology, Sant'Andrea Hospital, "Sapienza" University of Rome, Via di Grottarossa 1035-1039, 00198, Rome, Italy.
Curr Urol Rep. 2017 Sep;18(9):72. doi: 10.1007/s11934-017-0721-8.
We have reviewed the available evidence on the impact of long-term pharmacological treatment of lower urinary tract symptoms on the outcomes of benign prostatic hyperplasia surgery.
A systematic literature search from January 1990 to May 2017 was performed. Only references in the English language and peer-reviewed manuscripts were considered.
Over time, the ever-increasing use of long-term pharmaceutical treatments has considerably reduced the rate of BPH surgery in most countries. In addition, patients undergoing surgery are now generally older, more fragile and with larger prostates. Nevertheless, progress in the surgical field may have compensated for this critical picture and no pejorative trend has been recorded in peri- and post-operative complications and functional outcomes. The question whether long-term pharmacological treatment has altered the outcomes of surgical interventions of BPH remains with no clear answer. The call for randomized studies of long-term pharmacological vs surgical treatment of lower urinary tract symptoms due to BPH pharmacological treatment remains valid.
我们回顾了关于下尿路症状长期药物治疗对良性前列腺增生手术结局影响的现有证据。
进行了从1990年1月至2017年5月的系统文献检索。仅考虑英文参考文献和同行评审的手稿。
随着时间的推移，在大多数国家，长期药物治疗的使用不断增加，已大幅降低了良性前列腺增生手术的发生率。此外，现在接受手术的患者通常年龄更大、身体更虚弱且前列腺更大。然而，手术领域的进展可能弥补了这一严峻情况，在围手术期和术后并发症及功能结局方面未记录到不良趋势。长期药物治疗是否改变了良性前列腺增生手术干预的结局这一问题仍无明确答案。因良性前列腺增生药物治疗而呼吁开展下尿路症状长期药物治疗与手术治疗的随机研究仍然有效。
